Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testogel metabolic study in hypogonadism
ACTRN12616000577415Phase 4Completed
- Sponsor
- Western Sydney Local Health District
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of AndroForte in Hypogonadism, sponsored by Western Sydney Local Health District. Primary endpoint: Urea metabolism. Started Jan 2015; status: completed.
02
Drugs
AndroForte
03
Conditions
Hypogonadism
Beyond the preview
Go deeper on ACTRN12616000577415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000577415.